 Emmaus Life Sciences Inc OTCQX:EMMA CEO Yutaka Niihara said the company has made substantial progress in expanding access to Endari for sickle cell disease patients over 2021. Recently, the Torrance, California-based firm presented data from a post-hoc analysis of the Phase 3 clinical study of Endari, the companys prescription L-glutamine oral powder, in patients with sickle cell disease, that confirmed Endari meaningfully reduces both pain crises and hospitalizations. 